Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896158 | 0.85 | KIF11 (0.72) | KIF11CYP11B2CYP11B1 | |
| SCHEMBL12775032 | 0.84 | TDP1 (0.65) | KIF11ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL21116892 | 0.81 | KIF11 (0.76) | KIF11CYP11B2CYP11B1 | |
| SCHEMBL3895118 | 0.79 | KIF11 (0.64) | KIF11ALDH1A1CYP3A4TSHRCYP11B2 | |
| SCHEMBL28227135 | 0.79 | KIF11 (0.54) | KIF11CYP11B2CYP11B1 | |
| SCHEMBL3899873 | 0.79 | KIF11 (0.58) | KIF11CYP11B2CYP11B1 | |
| SCHEMBL3903111 | 0.78 | KIF11 (0.72) | KIF11CYP11B2CYP11B1 | |
| SCHEMBL3899619 | 0.78 | KIF11 (1.00) | KIF11CYP11B2CYP11B1 | |
| Orthotolidine SCHEMBL29365329 | 0.77 | CYP3A4 (1.00) | ALDH1A1CYP3A4TSHRTDP1 | |
| Orthotolidine SCHEMBL49414 | 0.77 | CYP3A4 (1.00) | ALDH1A1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706111-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885ALDH1A1 2715/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.